Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
20101.3k citationsDavid Grimwade, Robert K. Hills et al.Bloodprofile →
Association between premature mortality and hypopituitarism
2001817 citationsJeremy Tomlinson, N Holden et al.The Lancetprofile →
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial
2004612 citationsRobert K. Hills et al.The Lancetprofile →
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
2007522 citationsRosemary E. Gale, Alan K. Burnett et al.Bloodprofile →
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
2010490 citationsAlan K. Burnett, Robert K. Hills et al.Journal of Clinical Oncologyprofile →
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
2014479 citationsRobert K. Hills, Sylvie Castaigné et al.The Lancet Oncologyprofile →
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
2015346 citationsAlan K. Burnett, Nigel H. Russell et al.The Lancet Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Robert K. Hills
Since
Specialization
Citations
This map shows the geographic impact of Robert K. Hills's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert K. Hills with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert K. Hills more than expected).
This network shows the impact of papers produced by Robert K. Hills. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert K. Hills. The network helps show where Robert K. Hills may publish in the future.
Co-authorship network of co-authors of Robert K. Hills
This figure shows the co-authorship network connecting the top 25 collaborators of Robert K. Hills.
A scholar is included among the top collaborators of Robert K. Hills based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Robert K. Hills. Robert K. Hills is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Hills, Robert K., Sylvie Castaigné, Frederick R. Appelbaum, et al.. (2014). Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology. 15(9). 986–996.479 indexed citations breakdown →
Grimwade, David, Robert K. Hills, Anthony V. Moorman, et al.. (2010). Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. British Journal of Haematology. 149. 17–17.29 indexed citations
12.
Grimwade, David, Robert K. Hills, Anthony V. Moorman, et al.. (2009). REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS. Haematologica. 94. 217–217.5 indexed citations
McMullin, M. F., Ken Mills, Robert K. Hills, et al.. (2009). THE PROGNOSTIC ROLE OF C-FLIP IN AML. 94. 108–108.1 indexed citations
15.
Grimwade, David, Anthony V. Moorman, Robert K. Hills, et al.. (2004). Impact of karyotype on treatment outcome in acute myeloid leukemia.. Annals of Hematology. 83.17 indexed citations
16.
Harrison, Christine J., Anthony V. Moorman, Robert K. Hills, et al.. (2003). Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12.. Blood. 102(11). 333–333.3 indexed citations
17.
Hills, Robert K., et al.. (2003). PROSPER: A uniquely flexible randomised controlled trial in rectal prolapse repair. Controlled Clinical Trials. 24.2 indexed citations
18.
Grimwade, David, R P Gale, Robert K. Hills, et al.. (2003). The relationship between FLT3 mutation status: biological characteristics and outcome in patients with acute promyelocytic leukaemia.. Blood. 102(11).3 indexed citations
19.
Burnett, Alan K., Robert K. Hills, A H Goldstone, et al.. (2003). Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial. Blood. 102.4 indexed citations
20.
Tomlinson, Jeremy, et al.. (2001). Association between premature mortality and hypopituitarism. The Lancet. 357(9254). 425–431.817 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.